Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24132

Title: Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question
Authors: Burzykowski, Tomasz
Saad, Everardo D.
Buyse, Marc
Issue Date: 2017
Citation: JAMA ONCOLOGY, 3(3), p. 416-416
Notes: [Burzykowski, Tomasz; Saad, Everardo D.] Int Inst Drug Dev, 30 Ave Provinciale, B-1340 Louvain La Neuve, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Hasselt, Belgium. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA.
URI: http://hdl.handle.net/1942/24132
DOI: 10.1001/jamaoncol.2016.3941
ISI #: 000397491400023
ISSN: 2374-2437
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version36.91 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.